This Week
  • CFO David Klein is leader of the financial team at Constellation Brands.

  • CEO Eric Converse has VirtualScopics on the verge of generating cash.

  • MaeTec Power Inc. began as a part-time operation in 2003.

  • Renovations of buildings downtown are helping to give new life to the center city.

  • Mirror Show Management grabbed the top spot on the 2015 Rochester Top 100.

  • Liz Madison is bringing the farm to doorsteps across Wayne and Monroe counties.

Biotech firm Vaccinex begins clinical trial

Rochester Business Journal
January 7, 2013

Biotechnology firm Vaccinex Inc. has initiated a Phase I clinical trial to assess a therapeutic antibody candidate in patients with multiple sclerosis.

The trial will test the safety, tolerability and pharmacokinetics, or the analysis of the movement of drugs in the body. The antibody candidate, VX15/2503, targets the multi-functional protein semaphorin 4D and represents the second clinical trial for the investigational drug.

Studies have shown that anti-semaphorin 4D antibody can successfully ameliorate disease severity, officials said. Antibodies are proteins produced by the body as an immune response.

“It is particularly gratifying for Vaccinex to translate into the clinic the first therapeutic to target this important new class of regulatory molecules,” said Maurice Zauderer, president and CEO of Vaccinex, in a statement. “Research in our own and other laboratories has shown that the multiple activities of (semaphorin 4D) have a coordinated detrimental effect on progression of neurological diseases, several types of cancer and some other inflammatory and/or degenerative conditions.”

Vaccinex is completing a parallel trial of VX15/2503 antibody in patients with solid tumors, he said.

(c) 2013 Rochester Business Journal. To obtain permission to reprint this article, call 585-546-8303 or e-mail

What You're Saying 

There are no comments yet. Be the first to add yours!

Post Your Own Comment


Not registered? Sign up now!

To Do   Text Size
Post CommentPost A Comment eMail Size1
View CommentsView All Comments PrintPrint Size2
ReprintsReprints Size3
  • E-mailed
  • Commented
  • Viewed
RBJ   Google